Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

Creative Commons License

Brunner H., Foeldvari I., Alexeeva E., Ayaz N. A., Calvo Penades I., KASAPÇOPUR Ö., ...More

ANNALS OF THE RHEUMATIC DISEASES, vol.82, no.1, pp.154-160, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 82 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.1136/ard-2022-222849
  • Journal Name: ANNALS OF THE RHEUMATIC DISEASES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.154-160
  • Keywords: arthritis, juvenile, arthritis, psoriatic, biological therapy
  • Hacettepe University Affiliated: Yes

Abstract

Background Treatment options in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) are currently limited. This trial aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA with inadequate response to conventional therapy.